COFLU REMEDY

COFLU REMEDY

About COFLU REMEDY

Made in TAIWAN
COFLU REMEDY (NRICM101)康福濃縮顆粒(臺灣清冠一號)

About NRICM101
關於臺灣清冠一號

Due to the global COVID-19 pandemic, according to statistics the death toll has exceeded 4 million as of June, 2021
Experts from all over the world are working hard to develop medicines, vaccines, anti-epidemic supplies, etc. Work together to restart human health and normal life!
COVID-19病毒肆虐全球,全球死亡人數在2021年6月已超越400萬人。
世界各國的專家學者努力研製治療藥物、疫苗、防疫用品等等,一同為重啟人類健康與正常的生活努力!

Taiwan's epidemic prevention performance has been recognized by all countries in the world! The development of medicine is kept ahead of other countries; in 2003, Traditional Chinese medicine has successfully treated SARS corona virus. After clinical use of quinine (HQC) in the treatment of COVID-19 has failed, Taiwan National Research Institute of Chinese Medicine and Taiwan, Tri-Services General Hospital teamed up to bring up the medicine formula based on the experience of fighting SARS pandemic, NRICM101, use the Chinese medicine which are more than a thousand years as the base, developed with the principle of traditional Chinese medicine treatment and nursing care, has combined therapy of Chinese and Western. Clinically, it is not only effective in preventing and anti-viral but also effectively suppress cytokine storm. (Organ damage or failure due to excessive defensive behavior of the human immune system). The NRICM101 successfully cured many patients and exported to Europe.
臺灣在各界的努力下防疫表現倍受世界各國肯定!治療藥物的研製也不落人後; 2003年,中醫已有成功治療SARS冠狀病毒的經驗,在臨床使用奎寧(HQC)治療COVID-19新冠肺炎無效之後,臺灣中醫藥研究所與三軍總醫院合作,應用抗SARS成功經驗共同開發治療藥品,臺灣清冠一號(NRICM101),使用具千年藥用歷史的中藥材為基底,搭配中醫治療與調養並重的原則研發製成,已在臺灣採取中西醫合療,臨床上不僅在預防及抗病毒的效果卓越,還能有效抑制免疫風暴(因人體免疫系統的過度防禦行為導致器官損傷或衰竭)。已成功治癒多例患者並外銷歐洲,為台灣防疫佳績再添一筆!

Li Kang Biotechnology is a professional manufacturer in specializing multifunctional biotechnology products such as Western medicine, Chinese medicine, medical device and health products. Not only to meet the government’s demand for anti-epidemic materials, add mask production line; work harder to obtain the export drug license for NRICM101. To fight against the new crown pandemic with the people of overseas.LiKang strives to develop medical and healthcare products that meet the requirements with the international standards. We look forward to get the recognition and trust from global consumers, contribute to the people health.
「立康生物科技」專精於西藥、中藥、醫材及保健品等多功能生技產品的專業製造廠,不僅配合政府徵收防疫物資需求,增設口罩產線; 更努力取得「臺灣清冠一號(NRICM101) 」藥品外銷專用許可證,與海外各國民眾一同對抗新冠肺炎! 立康努力以國際觀標準研製符合世人要求的醫療保健產品,期許贏得全球消費者的肯定與信賴,為世人的健康盡一份心力。



Introduction of NRICM101
NRICM101 is the first traditional Chinese medicinal formulation that can be used to treat the global pandemic COVID-19. The formulation is developed by Taiwan’s Tri-Service General Hospital and the National Research Institute of Chinese Medicine. The clinical data shows that among 33 confirmed patients, there are 12 older, more severely ill patients who have been hospitalized for 21 days without improvement. After taking the NRICM101 and test negative three consecutive times within 9 days, no side effects or interaction between Chinese and Western medicine. This article has also been published in Biomedicine & Pharmacotherapy, an internationally renowned journal in the field of pharmacy.
臺灣清冠一號簡介
清冠一號是台灣第一個可用來治療新冠肺炎COVID-19的中藥複方水煎劑,由三總中醫部與國家中醫藥研究所合作研發。臨床的資料顯示,收治的33例確診患者中,有12位年齡較大、病情較重且住院21天無改善的患者。他們在服用清冠一號藥劑9天內,連續採檢獲得3次陰性結果,並且無任何副作用或中西藥交互作用。該文章也已發表在國際知名的藥學領域期刊Biomedicine & Pharmacotherapy。

NRICM101
The National Research Institute of Chinese Medicine develop the formula NRICM101. It has the mechanism of action with multiple targets and the the same effect as the vaccine.

  • The formula NRICM101 can inhibit virus infection and replication, and harmonize the cytokine storm by preventing corona virus spike protein binding with ACE2 so that the virus lose their way to enter human body and stop multiplying.
  • Inhibit 3 CL protease activity, block the replication of the virus.
  • Inhibit the cytokine secreted by alveolar macrophages TNF-α、IL-6 to regulate the inflammatory storm, reduce lung damage and reduce the development of pulmonary fibrosis
    In clinical treatment, COFLU Remedy can prevent illness from getting worse, helping recovery and reducing the chance of returning positive and length of stay.

國家中醫藥研究所研發中藥複方水煎劑「台灣清冠一號」具有多靶點的作用機轉,幾已等同疫苗的效用;
  • 抑制新冠病毒棘蛋白(Spike Protein)與宿主細胞膜上ACE2的結合,阻止病毒入侵細胞。
  • 抑制3CL蛋白酶的活性,阻斷病毒在細胞內的複製。
  • 抑制肺泡巨噬細胞分泌的細胞激素TNF-α、IL-6,來調控所產生的發炎風暴,減少肺部的破壞及降低肺纖維化的發展。
    在臨床治療上,急重症患者能扭轉病勢,在重症、輕症的患者治療上則可縮短病毒轉陰與住院時間。



相關網址連結: https://www.sciencedirect.com/science/article/pii/S0753332220312294

Clinically, those 12 patients were given NRICM101, 1 person with critical disease, 3 people with severe disease, 9 people with mild disease, no pulmonary fibrosis after treatmet. According to statistical analysis, the patients who treated with method of integrative care of Chinese and Western Medicine achieved 3 consecutive negative results and no adverse events. The number of days in hospital was significantly less than that of patients receiving western medicine treatment alone.
臨床上,清冠一號治療的12 位患者以中、西醫合作照護模式,其中危重症 1 人、重症 3 人、輕症 9 人,治癒出院後未出現肺纖維化。據統計,接受中西醫合作照護模式患者連續3次陰性測試的入院天數明顯少於僅接受西醫治療患者。

About COFLU REMEDY
關於康福濃縮顆粒

Treatment of traditional Chinese medicine in Asia regions such as Japan, South Korea, more than 4000 years history, NRICM 101 prescription on the antiviral resistance and reduce infection, regulating immunity and adjust physique, to block the course of the disease in patients and can accelerate healing and recovery, the chance of retest positive, the occurrence of severe complications after pulmonary fibrosis. This formula has also been tested by the Taiwan National Research Institute of Chinese Medicine for basic research, and has been proven to have good efficacy, and has been developed into a concentrated granule COFLU REMEDY for clinical use (NRICM 101) ".
中醫治病在中國韓國日本等華人地區,已有4000多年歷史,臺灣清冠一號 處方著重在對抗病毒抗邪減少感染、調節免疫力及調整體質,以阻斷患者病程發展、加速痊癒與體能恢復,並減少復陽、重症後肺纖維化併發症之發生。此藥物也經由國家中醫藥研究所進行基礎研究,獲得良好療效驗證,並開發成為可供臨床使用的康福濃縮顆粒(NRICM 101)。



IN 2021, Li Kang Biotechnical Co., Ltd. has been officially authorized by Taiwan’s National Research Institute of Chinese Medicine to manufacture and sell as COFLU REMEDY (NRICM101). We obtain the manufacturing license of Emergency Use Authorization and export license, which will be sold in overseas countries to reduce externally contracted seasonal epidemic.
2021年國家中醫藥研究所授權立康生物科技股份有限公司製造及銷售。已取得「緊急授權核准製造許可」及外銷專用藥品許可證。
銷售海外各國提供民眾減少外邪感染時疫之虞慮及支援國內檢疫所及中醫醫療院所使用,一同對抗新冠肺炎 !
History
    3Inquiry